A comprehensive continuous glucose monitoring system market region analysis shows that North America currently holds the largest market share, at approximately 39%. This dominance is supported by a well-established reimbursement landscape and the presence of industry titans like Dexcom and Abbott. In the United States, recent changes in Medicare coverage have made CGMs available to a much broader group of Type 2 patients, leading to a massive spike in adoption. The region’s focus on high-tech healthcare and rapid regulatory pathways ensures it will remain a leader in the global market.

However, the Asia-Pacific region is the fastest-growing territory, with India and China becoming critical markets due to their massive diabetic populations. In these countries, the shift from traditional glucometers to CGMs is being driven by rising disposable incomes and a growing middle class that prioritizes advanced medical technology. Meanwhile, Europe maintains a steady market share with a strong emphasis on "interoperability"—ensuring that CGMs from different brands can talk to various insulin pumps and apps. This open-platform approach in Europe is fostering a highly competitive environment that drives down costs for the end-user.